CL2014001062A1 - Metodo para tratar tumores del estroma gastrointestinal que comprende el uso de un inhibidor de c-hit y un inhibidor de pi3k o fgfr y combinacion que comprende a los compuestos. - Google Patents

Metodo para tratar tumores del estroma gastrointestinal que comprende el uso de un inhibidor de c-hit y un inhibidor de pi3k o fgfr y combinacion que comprende a los compuestos.

Info

Publication number
CL2014001062A1
CL2014001062A1 CL2014001062A CL2014001062A CL2014001062A1 CL 2014001062 A1 CL2014001062 A1 CL 2014001062A1 CL 2014001062 A CL2014001062 A CL 2014001062A CL 2014001062 A CL2014001062 A CL 2014001062A CL 2014001062 A1 CL2014001062 A1 CL 2014001062A1
Authority
CL
Chile
Prior art keywords
inhibitor
pi3k
hit
compounds
combination
Prior art date
Application number
CL2014001062A
Other languages
English (en)
Inventor
Fang Li
John E Monahan
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47116505&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2014001062(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CL2014001062A1 publication Critical patent/CL2014001062A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CL2014001062A 2011-10-28 2014-04-25 Metodo para tratar tumores del estroma gastrointestinal que comprende el uso de un inhibidor de c-hit y un inhibidor de pi3k o fgfr y combinacion que comprende a los compuestos. CL2014001062A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161552633P 2011-10-28 2011-10-28

Publications (1)

Publication Number Publication Date
CL2014001062A1 true CL2014001062A1 (es) 2014-10-10

Family

ID=47116505

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2014001062A CL2014001062A1 (es) 2011-10-28 2014-04-25 Metodo para tratar tumores del estroma gastrointestinal que comprende el uso de un inhibidor de c-hit y un inhibidor de pi3k o fgfr y combinacion que comprende a los compuestos.

Country Status (17)

Country Link
US (1) US20140288073A1 (es)
EP (1) EP2770999A1 (es)
JP (1) JP2014532647A (es)
KR (1) KR20140096035A (es)
CN (1) CN103889422A (es)
AU (1) AU2012328979B2 (es)
BR (1) BR112014009993A2 (es)
CA (1) CA2853095A1 (es)
CL (1) CL2014001062A1 (es)
IL (1) IL231943A0 (es)
MX (1) MX2014005130A (es)
RU (1) RU2014120792A (es)
SG (1) SG11201400543TA (es)
TN (1) TN2014000093A1 (es)
TW (1) TW201332550A (es)
WO (1) WO2013063000A1 (es)
ZA (1) ZA201401622B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
EP3822273B1 (en) 2012-06-13 2024-04-10 Incyte Holdings Corporation Substituted tricyclic compounds as fgfr inhibitors
EP2872142A1 (en) * 2012-07-11 2015-05-20 Novartis AG Method of treating gastrointestinal stromal tumors
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
TWI649318B (zh) 2013-04-19 2019-02-01 英塞特控股公司 作為fgfr抑制劑之雙環雜環
US20160095842A1 (en) * 2013-05-31 2016-04-07 Christine Fritsch Combination therapy containing a pi3k-alpha inhibitor and fgfr kinase inhibitor for treating cancer
JP6445573B2 (ja) 2013-10-17 2018-12-26 サルタル セラピューティクス エルティーディSartar Therapeutics Ltd ヒト患者の固形腫瘍の治療に用いるためのホスホジエステラーゼ阻害剤含有組成物
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
PE20171514A1 (es) 2015-02-20 2017-10-20 Incyte Corp Heterociclos biciclicos como inhibidores de fgfr
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
JP6860919B2 (ja) * 2015-11-19 2021-04-21 国立大学法人金沢大学 間葉系kras変異型がん治療剤
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
AU2019262195A1 (en) 2018-05-04 2020-12-24 Incyte Corporation Solid forms of an FGFR inhibitor and processes for preparing the same
CR20200591A (es) 2018-05-04 2021-03-31 Incyte Corp Sales de un inhibidor de fgfr
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
MX2022004513A (es) 2019-10-14 2022-07-19 Incyte Corp Heterociclos biciclicos como inhibidores de los receptores del factor de crecimiento de fibroblastos (fgfr).
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
PE20221504A1 (es) 2019-12-04 2022-09-30 Incyte Corp Derivados de un inhibidor de fgfr
EP4069696A1 (en) 2019-12-04 2022-10-12 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
CN112210541B (zh) * 2020-10-14 2022-11-15 上海市普陀区利群医院 一种胃肠道间质瘤耐药细胞模型及其构建方法和应用
WO2022261160A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
GB0202873D0 (en) 2002-02-07 2002-03-27 Novartis Ag Organic compounds
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
GB0510390D0 (en) * 2005-05-20 2005-06-29 Novartis Ag Organic compounds
GT200600316A (es) 2005-07-20 2007-04-02 Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.
GT200600315A (es) 2005-07-20 2007-03-19 Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida
JO2660B1 (en) * 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
EP1923053A1 (en) 2006-09-27 2008-05-21 Novartis AG Pharmaceutical compositions comprising nilotinib or its salt
EA019064B1 (ru) * 2007-04-11 2013-12-30 Экселиксис, Инк. Способы лечения рака с применением хинаксолинового ингибитора pi3k-альфа
CN102036963B (zh) 2008-05-23 2013-08-21 诺瓦提斯公司 作为蛋白酪氨酸激酶抑制剂的喹啉类和喹喔啉类衍生物
EP2297912A4 (en) * 2008-07-01 2016-11-30 Ikanos Communications Inc VECTORED DSL WITH REDUCED MEMORY
UA104147C2 (uk) * 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань

Also Published As

Publication number Publication date
WO2013063000A1 (en) 2013-05-02
AU2012328979B2 (en) 2016-04-21
RU2014120792A (ru) 2015-12-10
TW201332550A (zh) 2013-08-16
CA2853095A1 (en) 2013-05-02
NZ622155A (en) 2015-12-24
SG11201400543TA (en) 2014-08-28
JP2014532647A (ja) 2014-12-08
KR20140096035A (ko) 2014-08-04
EP2770999A1 (en) 2014-09-03
BR112014009993A2 (pt) 2017-04-25
US20140288073A1 (en) 2014-09-25
TN2014000093A1 (en) 2015-07-01
AU2012328979A1 (en) 2014-05-15
IL231943A0 (en) 2014-05-28
ZA201401622B (en) 2015-12-23
CN103889422A (zh) 2014-06-25
MX2014005130A (es) 2014-08-27

Similar Documents

Publication Publication Date Title
CL2014001062A1 (es) Metodo para tratar tumores del estroma gastrointestinal que comprende el uso de un inhibidor de c-hit y un inhibidor de pi3k o fgfr y combinacion que comprende a los compuestos.
CL2014001065A1 (es) Compuestos derivados de piridopirazinas; composicion farmaceutica que los comprende; y su uso para la prevencion o el tratamiento de un estado patologico o afeccion mediada por una fgfr cinasa tal como cancer.
DK3436461T3 (da) Pyrrolotriazinforbindelser som tam-inhibitorer
DK3442980T3 (da) Heterocykliske forbindelser som ret-kinase-hæmmere
DK3119762T3 (da) Benzimidazol-derivater som erbb-tyrosin-kinase-inhibitorer til behandlingen af kræft
CL2014001793A1 (es) Compuestos derivados de 1,3,5-triazinas sustituidas y sus sales, como inhibidores de la idh2 mutante; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer.
CR20140223A (es) Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a
DK3030227T3 (da) Vedvarende frigivelses-doseringsformer for en jak1-inhibitor
DK3495367T3 (da) Substituerede tricykliske forbindelser som fgfr-inhibitorer
DK3181567T3 (da) Pyrazolopyrimidinforbindelser som kinasehæmmere
CL2015001377A1 (es) Inhbibidores de bmi-1 primidinas sustituidas inversas
DK3071561T3 (da) Autotaxininhibitorforbindelser
DK3293186T3 (da) Pyrimidinoner som faktor xia-hæmmere
CL2014000887A1 (es) Compuestos derivados de 1-fenil-imidazol condensado y sus sales, inhibidores de proteinas quinasas; composicion farmaceutica que los comprende; y su uso para el tratamiento de una condicion donde se desea la inhibicion de la quinasa del fgfr tal como cancer.
DK3087071T3 (da) Tricykliske forbindelser som anticancermidler
DK3080057T3 (da) Gødningsmiddelblanding indeholdende nitrifikationshæmmer
DK3321262T3 (da) Serin-/threoninkinasehæmmere
CL2015000177A1 (es) Composición para el tratamiento de la hiperlipidemia que comprende un derivado de oxintomodulina
CL2014002873A1 (es) Compuestos derivados de pirimidin-amina o triazin-amina, inhibidores de adn-pk; composicion farmaceutica; y su uso para el tratamiento del cancer.
DK3066085T3 (da) Fremgangsmåde til syntesen af en indolamin-2,3-dioxygenaseinhibitor
CO6842016A2 (es) Terapia de combinación que comprende un inhibidor de cdk4/6 y un inhibidor de pi3k para el uso en el tratamiento de cáncer
CR20210079A (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
ES2897914T8 (es) Compuestos que contienen nitrógeno, adecuados para el uso en la producción de poliuretanos
BR112014000033A2 (pt) compostos para o tratamento de dependência química
DK3533796T3 (da) Aminopyrazolopyrimidinforbindelse anvendt som neutrof faktor tyrosinkinasereceptor inhibitor